Testing effectiveness (Phase 2)Looking for participantsNCT07328503
What this trial is testing
CD22 CAR T-cells to Extend Remission Following Commercial CD19 CAR T-cells in Children, Adolescents, and Adults With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
Who this might be right for
Acute Lymphoblastic LeukemiaB-All
National Cancer Institute (NCI) 20